UN Commission on Narcotic Drugs Votes On Recommendations For Cannabis And Cannabis-Related Substances

AUSTRIA:  December 2, 2020 – Today, the Commission on Narcotic Drugs (CND) took a number of decisions on the international control of cannabis and cannabis-related substances.

Cannabis and cannabis-related substances have for many years been included in the schedules of the Single Convention on Narcotic Drugs of 1961 as amended by the 1972 Protocol (Schedule I and IV: cannabis and cannabis resin; Schedule I: extracts and tinctures of cannabis), as well as in the Schedules of the Convention on Psychotropic Substances of 1971 (Schedule I: tetrahydrocannabinol (six isomers of delta-9- tetrahydrocannabinol); Schedule II: dronabinol and its stereoisomers (delta-9-tetrahydrocannabinol)). The inclusion in a specific schedule determines the control measures that States parties are required to apply to the respective substances.

In January 2019, the World Health Organization (WHO) made a series of recommendations to change the scope of control of cannabis and cannabis-related substances. After intensive considerations (more information below), the Commission took action today on these recommendations.

WHO recommendation to delete cannabis and cannabis resin from Schedule IV of the 1961 Convention, but to maintain it in Schedule I of the 1961 Convention: The Commission decided by 27 votes to 25 and with one abstention to follow this recommendation. Cannabis and cannabis resin will accordingly be deleted from Schedule IV of the 1961 Convention. They remain in Schedule I of the 1961 Convention and thus remain subject to all levels of control of the 1961 Convention.

WHO recommendation to move dronabinol and its stereoisomers (delta-9-tetrahydrocannabinol) and tetrahydrocannabinol (six isomers of delta-9-tetrahydrocannabinol), which are psychoactive components of cannabis, from the respective schedules of the 1971 Convention to Schedule I of the 1961 Convention, which already includes cannabis and cannabis resin: The Commission rejected by 23 votes to 28 with 2 abstentionsthe recommendation to add dronabinol and its stereoisomers (delta-9-tetrahydrocannabinol) to Schedule I of the 1961 Convention. Due to the conditionalities included in the WHO recommendations, the Commission therefore did not vote on the recommendation relating to the deletion of dronabinol and its stereoisomers (delta-9-tetrahydrocannabinol) from the 1971 Convention. It also did not vote on the recommendation to move tetrahydrocannabinol (six isomers of delta-9-tetrahydrocannabinol) from the 1971 Convention to the 1961 Convention.

WHO recommendation to delete extracts and tinctures of cannabis from Schedule I of the 1961 Convention: The Commission decided by 24 votes to 27 and with 2 abstentions not to adopt this recommendation.

WHO recommendation to add a footnote to Schedule I of the 1961 Convention to read “Preparations containing predominantly cannabidiol and not more than 0.2 per cent of delta-9-tetrahydrocannabinol are not under international control”: The Commission decided by 6 to 43 votes and with 4 abstentions not to add such a footnote.

Lastly, WHO recommendation to add certain preparations of dronabinol to Schedule III of the 1961 Convention: As the Commission had predetermined in a procedural decision, adopted at the beginning of the meeting, this recommendation was deemed rejected, due to the rejection of the recommendation to add dronabinol and its stereoisomers (delta-9-tetrahydrocannabinol) to Schedule I of the 1961 Convention.

CEI Leads Coalition Letter Supporting MORE Act Provision To De-Schedule Cannabis

Dear Speaker Pelosi, Leader Hoyer, Leader McCarthy, and Whip Scalise:

On behalf of the many of Americans whose views and values our organizations represent, we respectfully urge you to support efforts to remove cannabis from the Controlled Substances Act. While we oppose many aspects of the Marijuana Opportunity Reinvestment and Expungement (MORE) Act, we support its provision to de-schedule cannabis, which would restore the right to decide how to regulate the substance to the people and their state representatives. The undersigned organizations agree that this action is an important step toward undoing the harms caused by the misguided drug war and protecting our nation’s principle of federalism.

In the past election, voters in five states authorized medical cannabis use, recreational use, or both. In fact, every cannabis-legalization ballot measure throughout the country was approved by voters, bringing the total number of states that have legalized medical cannabis to 35 plus the District of Columbia and the number of states that have legalized recreational cannabis use for adults to 15, along with the District. In fact, all but two states have legalized or decriminalized cannabis in some form, properly adapting state policies to reflect the needs and opinions of their constituents. Yet, such responsive governance is hampered by the fact cannabis remains federally prohibited.

Congress has recognized the need to resolve this conflict for many years. Amendments to prevent federal interference in state cannabis regulation enjoy a long history of support among both House Republicans and Democrats. These measures can give states some flexibility to set policies in accordance with the will of their people. But the dual legal status of cannabis has created confusion and put the welfare of many citizens and businesses in jeopardy.

The federal prohibition has excluded small cannabis businesses from many of the financial and legal services or benefits afforded to other industries. The conflict also creates hazards for consumers of legal cannabis products, extending to issues of employment, housing, property rights, firearms purchasing, and civil asset forfeiture, among others. For example, patients who wish to participate in their state’s legal medical marijuana program must choose between their medicine and owning a gun, because the Gun Control Act of 1968 prohibits anyone who uses controlled substances from possessing guns or ammunition. Only Congress can resolve this conflict and there is strong, bipartisan public support for such action.

According to a November 2020 Gallup poll, 68 percent of all Americans believe the use of marijuana should be made legal, including 52 percent of Republican voters. There is even greater support for allowing states to make the decision without federal interference. A 2017 CBS News Poll found that 64 percent of Republican voters, 76 percent of Democrats, and 72 percent of independents opposed federal attempts to stop states from legalizing cannabis.

The undersigned organizations vary in our opinions on the specifics of cannabis legalization, but we are in strong accord when it comes to whether the federal or state governments should have the power to make such decisions. Our Constitution limits federal power and leaves most issues of law enforcement to the individual states for good reason. We are a nation of diverse backgrounds, opinions, and values. State authorities are best placed to understand the needs of their populace and must be free to decide how best to protect public health and safety and direct limited resources toward those priorities. What works for California may not be appropriate for Utah and vice versa. The federal government need not endorse one approach or another nor condone cannabis use; it needs only to respect the states’ authority to choose how best to regulate cannabis.

As a coalition of groups and individuals supporting free market solutions and the protection of essential constitutional principles, we strongly urge you to respect our nation’s federalist structure and support the MORE Act’s provision to de-schedule cannabis.

Sincerely,

Michelle Minton
Senior Fellow
Competitive Enterprise Institute

Andrew Langer
President, Institute for Liberty

David Williams
President
Taxpayers Protection Alliance

Arthur Rizer
Director of Criminal Justice & Civil Liberties Policy
R Street Institute

California Bureau Of Cannabis Control Announces Public University Research Grant Funding Recipients

CALIFORNIA: The Bureau of Cannabis Control (Bureau) announced that it has awarded $29,950,494 in public university research grant funding to universities across California.

“The research conducted through these public university grants will provide critical information for evaluating our legal cannabis system and its impacts,” Bureau of Cannabis Control Chief Lori Ajax said. “This research will be a valuable tool to inform future cannabis policy in California.”

Research proposals had to fall within one of the several specified categories, including public health, criminal justice and public safety, economic, environmental impacts, and the cannabis industry. A detailed description of the list of research subjects for grant funding can be found in Revenue and Taxation Code section 34019.

In total, the Bureau received more than 100 applications for grant funds up to $2 million for any specific proposal. After a thorough review process, the nearly $30 million was awarded to the following public universities:

Public University Awarded Funding Research Proposal
UC San Francisco  

$2,000,000.00

Comprehensive Analysis of Developmental Cannabis Exposure on Brain, Immune, and Sensory Systems
 

UC Santa Barbara

 

$1,999,191.00

Surface Water Emissions from Cannabis Cultivation Sites: Quantity, Quality, Toxicity, and Relationships to Farmers’ Practices
CSU

Dominguez Hills

 

$1,866,311.00

 

Cannabis Industry in South Bay Los Angeles

UC

Berkeley

$1,827,596.00 Local Regulation of Cannabis in California
UC Los Angeles  

$1,429,001.00

Impact of Cannabis Potency on The Properties, Composition, and Toxicity of Inhaled and Second-Hand Smoke
UC San Francisco $1,384,466.00 Effects of Chronic Cannabis Use on Endothelial Function
 

UC Irvine

 

$1,351,556.00

Exploring Cannabis Policies and Practices That Influence Adolescent Use: Evolution of Local Cannabis Law, Products, Sales, and Marketing
 

UC San Diego

 

$1,321,833.00

The Public Health Impact of Cannabis Legalization in California: A Comprehensive Qualitative and Quantitative Analysis by Age, Gender, Race/Ethnicity, and Regions
UC Los Angeles  

$1,082,815.00

Assessing the Feasibility and Consequences of Implementing a Cannabis Potency Tax in California
UC San Francisco  

$1,067,483.00

The LEAF Study: Lung Effects and Function Associated with Cannabis Use
UC Los Angeles  

$1,048,857.00

Study of Employment Conditions and Equity in California’s Cannabis Industry
 

UC San Francisco

 

$1,038,782.00

Public Health Impacts of State Policies Mandating Point-of- Sale Warning Signs Regarding Cannabis Use During Pregnancy
UC Davis $1,034,730.00 Understanding the Impact of Cannabis Use in Early Psychosis
UC San Diego  

$987,738.00

Evaluating the Impacts of Packaging and Labeling on Cannabis Edible Use among Youth
UC San Francisco $952,540.00 California Cannabis Poisonings Under Proposition 64
 

UC Los Angeles

 

$896,794.00

Assessing the Impact of Proposition 64 on Cannabis Use, Maladaptive Cannabis Use, Cannabis Use Disorder Treatment, and Public Health
UC San Diego  

$887,101.00

The Role of Cannabidiol in Anandamide-Related Improvement in Alexithymia and Health Outcomes
UC Los Angeles  

$781,707.00

A Demographic Analysis of the California Licensed Cannabis Industry and Consumer Market
UC Los Angeles  

$758,517.00

The Impact of Cannabis Marketing on California’s Youth: Neuro-Behavioral Studies for Informing Policy
 

 

UC Davis

 

 

$726,816.00

Cannabis Industry: Assessment of the Location, Structure, Function, and Demographics of Licensed Cannabis, Focusing on Geographical Price Differences, and Differential Impacts of Local Prop-64 Related Regulations on the Competitiveness of Licensed Businesses
UC

Berkeley

 

$658,306.00

Transformation of Unregulated Cannabis Cultivation Under Proposition 64
 

 

UC Davis

 

 

$655,564.00

Economic Impacts: Market Prices for Licensed and Unlicensed Cannabis and the Effects of the Current and Alternate Cannabis Tax Structures and Tax Rates on the Private and Public Sectors in California, Including Government Administrative Costs and Revenues
 

 

UC Davis

 

 

$562,240.00

Environmental Impacts of Cannabis Cultivation in California As Affected by the Farm Economics of Licensed and Unlicensed Cannabis Production, Including Effects of Testing Regulations and Compliance with the Criminal Prohibition of Unlicensed Cannabis
 

UC

Berkeley

 

 

$489,762.00

Assessing Environmental Impacts of Cannabis-Related Noise and Light Disturbance to Inform Management of California Wildlife
UC

Berkeley

 

$465,902.00

Examining Tribal Sovereignty Over Cannabis Permitting on Native Ancestral Lands
CSU

Humboldt

$464,997.00 Cannabis Business Entrepreneurs and Jobs
UC Los Angeles  

$414,183.00

Understanding the Impact of Cannabis Marketing on Cannabis Use Disparities Among Sexual and Gender Minority Youth
UC

Berkeley

 

$328,916.00

Cultivation Bans, Local Control, and the Effects and Efficacy of Proposition 64
UC

Berkeley

 

$319,091.00

Cannabis and Wildfire: Current Conditions, Future Threats, and Solutions for Farmers
UC

Berkeley

 

$314,417.00

Cannabis Water-Use Impacts to Streamflow and Temperature in Salmon-Bearing Streams
UC

Berkeley

$270,269.00 The Effect of Local Cannabis Regulation on Property Prices
UC San Diego  

$235,039.00

Evaluating Risks and Benefits of Cannabis Use by Older Adults: A Pilot Study
CSU

Humboldt

 

$183,015.00

The Economic Impact of Cannabis Legalization in Rural Northern California
 

UC Davis

 

$144,949.00

California Cannabis Workers: Perceptions, Beliefs, and Knowledge of Occupational Health and Industry Hazards

Curio Wellness Launches Investment Fund To Combat Diversity And Inclusion Challenges Within Cannabis Industry

$30 Million in Capital will Provide 50 Diverse Entrepreneurs with Up to Ninety-Three Percent of the Capital Needed to Open a Curio Franchise in any one of eight states.

MARYLAND: Curio Wellness today announced a new funding program that will provide start-up capital for minority business owners to open their own Curio Wellness franchise location. Created for women, minorities and disabled veterans, Curio Wellness’s investment fund (the Fund) will allow the medical cannabis and wellness company to further its goal of serving patients with safe, effective and reliable cannabis-based medicine in multiple states through its unique Wellness Center retail business concept. A legally separate but affiliated entity from Curio Wellness, the Fund will connect diverse investors with up to 50 aspiring women, minority and disabled veteran entrepreneurs, providing $30 million in capital funding.

“In looking at the systemic barriers that women, minorities and disabled veterans face in accessing capital, we decided to develop a solution that directly addresses this massive economic disparity,” said Michael Bronfein, CEO. “The Fund provides qualifying entrepreneurs with the investment capital they need to become a Curio Wellness Center franchisee, while ensuring their success through our best in class business operations.”

Banks and other traditional financing sources generally do not provide equity, capital or loans for cannabis start-ups. While this hurts all potential cannabis business owners, it disproportionately impacts women, minorities and disabled veterans. Through the support of committed and diverse investors, the Fund will eliminate the most significant barrier preventing diverse participation in this burgeoning, rapidly growing industry: a lack of capital in concert with a proven business model and brand.

The Fund will invest in up to 50 women, minority and disabled veteran entrepreneurs seeking to open a Curio Wellness franchise location in states with thriving medical cannabis programs. The $30 million Private Equity Fund will expand diversity and enable economic empowerment by providing up to ninety-three percent of the start-up capital needed to launch a branded dispensary. Eligible entrepreneurs, through partnership with the Fund, will be enabled to launch a franchise as the majority owner from day one and enjoy a clear pathway to full ownership as a franchisee.

“The Fund will expand diversity and enable economic empowerment for entrepreneurs who otherwise would be locked out of the rapidly growing field,” said Jerel Registre, Director of Business Development at Curio Wellness and Managing Director of the Fund. “Our diverse set of entrepreneurs will repay the startup loans with their portion of the dispensary earnings, resulting in 100% ownership as a franchisee over time.”

The application process to become a Curio franchisee is expected to open in early 2021 as Curio is approved to establish franchises. The Fund will soon announce its first closing and is expecting to have a final closing before year end.

Virginia Governor Northam Releases Report On Marijuana Legalization

Community-driven report reflects recommendations of the Virginia Marijuana Legalization Work Group

VIRGINIA:  Governor Ralph Northam today released the Administration’s report on the impact of legalizing adult-use marijuana in the Commonwealth of Virginia.

The report is the final product of the Virginia Marijuana Legalization Work Group, and it results from a diverse, stakeholder-driven process that involved community leaders, healthcare professionals, policy experts, and government officials. This months-long effort was a key part of marijuana decriminalization legislation passed by the General Assembly earlier this year, and follows Governor Northam’s recent announcement that he intends to advance marijuana legalization in Virginia.

“We will advance new laws to make sure that our Commonwealth legalizes marijuana the right way,” said Governor Northam. “Virginia has studied the experience of other states and this report lays out a path forward that leads with social equity, public health, and public safety.”

The comprehensive report includes nearly 400 pages of meeting minutes and outlines various aspects of marijuana legalization in the Commonwealth, including taxation, banking, criminal justice, licensing and regulation, and consumer safety. It also provides additional details on the five key principles that Governor Northam wants to see in any final legalization bill:

  • Social equity, racial equity, and economic equity. Marijuana prohibition historically has been based in discrimination, and criminalization laws have disproportionately harmed minority communities. Legislation should focus on undoing these harms by including initiatives such as social equity license programs, access to capital, community reinvestment, and sealing or expunging records of past marijuana-related convictions.
  • Public health. Legislation should include substance abuse prevention efforts in schools and communities.
  • Protections for young people. As a pediatrician, Governor Northam will require any legislation include protections for Virginia’s youth, including age limits, mandatory ID checks, and education campaigns.
  • Upholding the Virginia Indoor Clean Air Act. Legislation should be aligned with the Virginia Indoor Clean Air Act prohibiting indoor tobacco use, which Governor Northam championed as a state Senator.
  • Data collection. Legislation should ensure Virginia collects appropriate and ongoing information on safety, health, and equity.

The Virginia Marijuana Work Group consulted with dozens of subject matter experts in compiling its recommendations, including organizations focused on ensuring social and racial equity, such as the Minority Cannabis Business Association, NoLef Turns, and Decriminalize Virginia. Health experts, including public health policy consultants and practicing physicians were extensively involved, and the team worked closely with government officials from states that have already legalized marijuana, such as Washington, Massachusetts, and Illinois.

The Work Group was led by the Secretaries of Agriculture and Forestry, Finance, Health and Human Resources, and Public Safety and Homeland Security. The group held a total of 15 public meetings between July and October 2020.

The full report is available here. Additional information about the Virginia Marijuana Work Group and its membership can be found here.

Missouri Health & Wellness Announces Grand Opening for Cannabis Dispensary in Washington

MISSOURI: Missouri Health & Wellness (MH&W), a medical cannabis company licensed to operate five dispensaries in the state, announced today that its Washington location will be open for business on November 30 th. The Washington location is one of five dispensaries operated by MH&W and was one of the first approved by the Missouri Department of Health and Senior Services (DHSS) to operate in the state. MH&W also owns and operates dispensaries in Belton, Kirksville, Jefferson City and Sedalia.

“This has been a long time coming and we are excited to finally bring medical cannabis to Washington, Franklin County and the surrounding areas,” said Randy Stambaugh, MH&W’s statewide manager. “I can’t say enough about the support we have received from the City of Washington, the business community and the residents.”

OLCC Approves Recreational Marijuana License Stipulated Settlements

Receives updates on Portland’s Cannabis Equity program, Voter-approved ballot measures

OREGON:  At its regular monthly meeting on November 19, 2020, the Oregon Liquor Control Commission approved eight recreational marijuana license stipulated settlements. Additionally, the City of Portland’s Cannabis Policy Oversight Team (CPOT) provided the Commission with an update on the Portland Cannabis Program.

CPOT reviewed its efforts to make equity the center of all decision-making efforts related to cannabis regulation, including ensuring that patients should have access to cannabis for medicinal purposes. CPOT is also reworking its cannabis grant program to focus on distributed funding to BIPOC recipients.

OLCC staff provided assessments of how two ballot measures approved by Oregon voters earlier this month could impact the agency.

Measure 109, which establishes a program for the therapeutic use of psilocybin mushrooms directs the Oregon Health Authority (OHA) to enter into an agreement with the OLCC to use the state’s Cannabis Tracking System (CTS) to prevent psilocybin diversion from therapy program. OLCC has initiated conversations with its CTS vendor the OLCC has deferred further action, until OHA currently busy with pandemic can begin implementing the program.

One provision of Measure 110 reclassifies some drug convictions which will impact the evaluation process of OLCC licensee and permitee applicants. Currently the OLCC rarely makes a license or permit decision based solely on drug convictions, but there are differences between the OLCC’s alcohol and recreational marijuana licensing and permitting criteria that will now be reconciled; this might require the OLCC to enter into rulemaking.

The Commission also ratified the following violation fines and suspensions based on stipulated settlements (detailed information on specific cases can be found here on the OLCC website):

LA MOTA (#28CC) in Portland will serve an 18-day recreational marijuana retailer license suspension OR pay a fine of $2,970 fine for two violations.

Licensee is: La Mota, LLC, Co-Licensee; Aaron Mitchell, Member; Rosa Cazares, Co-Licensee.

VIBRANT HIGHS will surrender its marijuana processor license suspension for one violation.

Licensees are: OGX, LLC; Paul Luttrell, Member; Jonathan Showker, Member; Kathy Cook, Member.

 LA MOTA FRONT AVE in Portland will serve a nine-day recreational marijuana retailer license suspension OR pay a fine of $1,485 fine for one violation.

Licensees are: La Mota Front Ave, LLC, Co-Licensee; Aaron Mitchell, Member; Rosa Cazares, Co-Licensee.

EVIO LABS MEDFORD in Medford will surrender its recreational marijuana laboratory license suspension for four violations.

Licensees are: Smith Scientific Industries, Inc.; Anthony Smith, President/Director/Stockholder; William Waldrop, Secretary/Director; EVIO, Inc., Stockholder; Lori Glauser, Director/Stockholder; William Waldrop, Director/Stockholder.

MR NICE GUY RETAIL in Corvallis will serve a 10-day recreational marijuana retailer license suspension OR pay a fine of $3,630 fine for two violations.

Licensees are: MNG Holdings, LLC; Michael NG, Member; Patrick Martin, Member.

MR NICE GUY RETAIL in Salem will pay a fine of $280 for one recreational marijuana retailer license violation.

Licensees are: MNG Holdings, LLC; Michael NG, Member; Patrick Martin, Member.

NECTAR in Salem will serve a seven-day recreational marijuana retailer license suspension OR pay a fine of $1,155 fine for two violations.

Licensees are: Nectar Markets, LLC; Nectar Holdings, Inc., Member; Jeremy Pratt, President/Director/Stockholder; Jeffrey Johnson, Vice-President; Michael Olson, Secretary/Treasurer.

ALBION FARMS will serve an 18-day recreational marijuana producer license suspension OR pay a fine of $2,970 fine for two violations.

Licensees are: MediRec, LLC; Vandaly Industries, Inc., Member; Eric Buckner, President.

GKUA Ultra Premium Brings Its Celebrated Cannabis Line To Michigan’s Top Dispensaries

CALIFORNIA: GKUA Ultra Premium, the cannabis brand owned by Lil Wayne, the artistic giant and connoisseur of cannabis, announced today that their highly sought-after cannabis products and strains will be available across Michigan in select dispensaries.

“GKUA is Weezy’s Weed. It’s what I love, and now I’m sharing what I love with the people of Michigan,” said Lil Wayne. “These days everyone could use some help to feel inspired.”

GKUA Ultra Premium launched last December in California to great fanfare, bringing to market the best cannabis products in the world with some of the highest natural levels of THC available. GKUA Ultra Premium flower is sourced from the most experienced growers, who produce strains that are very limited, incredibly potent and rare in the world of cannabis. Now those strains, along with a complete line of cannabis products, will be available in Michigan, a market that moved to adult-use at the end of 2019. Since then, its recreational market has matured rapidly. In June, adult-use marijuana sales in the state surpassed medical cannabis sales, and Marijuana Business Daily expects the state to reach $1.9$2.4 billion by 2024.

“We are thrilled to expand GKUA Ultra Premium into the Michigan community, ensuring residents have access to the worlds-best cannabis products,” said Beau Golob, President and Co-founder GKUA Inc.  “Working with Lil Wayne is an honor, and we’ve found success in California through his unique vision of curating a premium line of products that inspires people and feeds their creativity. We’re sure those values will resonate with the residents of Michigan, a state known for its deep love of music and artistry.”

To celebrate the launch, Lil Twist, the rapper and reality television star, signed to Lil Wayne’s Young Money Entertainment music label, will visit dispensaries in Michigan where GKUA is being distributed. Lil Twist will be meeting fans and giving away swag. The tour, planned for October 10th, will include House of Dank 8 Mile (Detroit, MI), Herbology (River Rouge, MI) and The Clinic (Centerline, MI). For a full list of GKUA retailers in Michigan, use the Weezy Weed Finder on GKUA.com

In order to bring GKUA Ultra Premium to market in Michigan, the company partnered with Choice Labs. At launch, the following GKUA Ultra Premium products will be available in select Michigan dispensaries:

  • GKUA Ultra Premium Flower: Sourced from the most experienced growers, GKUA produces strains that are limited, incredibly potent and impossibly difficult to find…truly the best flower! Available at launch are two ultra premium Indica strains, Sour Garlic Cookies and Gorilla Glue #4.

  • GKUA Ultra Premium Battery Technology: The proprietary ceramic heating element and cutting-edge design is optimized to efficiently deliver vape in easily controllable doses while elevating the user experience. The battery technology combined with GKUA Ultra Premium THC is the future of vape.

  • GKUA THC Vape:  Sourced from the best cannabis strains, GKUA’s THC Vape is an exclusive formulation that carefully transforms the highest-quality cannabis into potent THC vape oil. Independently lab tested and certified for purity. GKUA Ultra Premium vape oil, pure and potent.

  • GKUA Ultra Premium Concentrates: Intensely potent and flavorful, GKUA Ultra Premium Concentrates are sourced from the finest cannabis flower with off-the-chart THC levels created for dabbing or adding to flower. Potency you can taste and feel.

  • GKUA Ultra Premium Pre-Rolls: GKUA Ultra Premium Pre-Rolls are made from the finest GKUA flower. Perfectly rolled for a smooth burn, these joints make taking the party with you easy.

About GKUA Ultra Premium
Lil Wayne, artistic giant and connoisseur of cannabis, has created the ultimate cannabis brand, GKUA Ultra Premium. Lil Wayne provides inspiration to millions of people, and now he is delivering it in one more form, the best high of your life. Produced from the finest cannabis, GKUA Ultra Premium products are Lil Wayne tasted and approved. GKUA strives to inspire artists and dreamers and supports the arts through collaborations with new artists in multiple mediums. GKUA Ultra Premium products are available in select California dispensaries. For more information about GKUA Ultra Premium products and events, visit gkua.com.

California BCC Rolls Out “Weedwise” Cannabis Consumer Survey

The Bureau of Cannabis Control’s (BCC) “Get #weedwise” campaign is currently collecting feedback from a variety of cannabis consumers on their current level of awareness of legal cannabis and consumer purchase behavior.

Since the pandemic began many consumers have shifted their habits and more cannabis consumers have entered the market. It’s important for the BCC to ensure the #weedwise campaign is as effective as possible. That is why the BCC has created a Google Forms survey to better understand how consumer buying habits have changed.

The survey allows you to remain anonymous and takes 2-3 minutes to complete: https://forms.gle/fwqpK7uWcQMm5f7QA.

Ohio Medical Marijuana Advisory Committee November 2020 Meeting Agenda

 

OHIO: The Medical Marijuana Advisory Committee will hold a meeting virtually via Skype on November 12, 2020.

AGENDA MEDICAL MARIJUANA ADVISORY COMMITTEE MEETING

November 12, 2020 10:00 a.m.

The Advisory Committee meeting will be held virtually via Skype.

Instructions to access the Skype Meeting will be posted here the morning of November 12, and via email update.

NOTE: The Advisory Committee will not be accepting testimony or public comments at this meeting.

10:00 a.m.

ROLL CALL AND MINUTES REVIEW

▪ Advisory Committee Members

10:05 a.m.

MEDICAL MARIJUANA CONTROL PROGRAM UPDATE

▪ Patient and Caregiver Update (Maerten-Moore)

▪ Dispensary Update (Maerten-Moore)

▪ Program Update (Maerten-Moore)

▪ Patient Survey Results (Maerten-Moore)

▪ Commerce Licensee Updates (McIlvaine)

▪ Program Sales and Product Data (McIlvaine)

▪ Commerce Initiatives (McIlvaine)

▪ Petitions for Qualifying Conditions (Pollock) o Current petition period and criteria o 2021 petition period dates

▪ Physicians with a CTR (Pollock)

▪ COVID-19 Update (Pollock)